{"id":1569,"date":"2023-03-10T10:30:00","date_gmt":"2023-03-10T02:30:00","guid":{"rendered":"https:\/\/vcro.online\/?p=1569"},"modified":"2024-07-12T10:31:00","modified_gmt":"2024-07-12T02:31:00","slug":"congratulations-allogeneic-stem-cell-for-cardiovascular-disease-treatment-has-received-tfda-approval-for-phase-i-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.vcro.com.tw\/?p=1569","title":{"rendered":"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial!"},"content":{"rendered":"\n<p>In February 2023, the professional team from VCRO assisted the client in submitting an allogeneic umbilical cord mesenchymal stem cell product for clinical trials in the field of cardiovascular diseases to TFDA. The team successfully obtained TFDA approval to proceed with Phase I clinical trials, helping the client smoothly transition to the clinical trial phase.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In February 2023, the professional team from VCRO assisted the client in submitting an allogeneic umbilical cord mesenchymal stem cell product for clinical trials in the field of cardiovascular diseases to TFDA. The team successfully obtained TFDA approval to proceed with Phase I clinical trials, helping the client smoothly transition to the clinical trial phase.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-1569","post","type-post","status-publish","format-standard","hentry","category-vcro-express"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\r\n<title>Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial! - VCRO<\/title>\r\n<meta name=\"description\" content=\"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial! VCRO -\" \/>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/www.vcro.com.tw\/?p=1569\" \/>\r\n<meta property=\"og:locale\" content=\"en_US\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial! - VCRO\" \/>\r\n<meta property=\"og:description\" content=\"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial! VCRO -\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/www.vcro.com.tw\/?p=1569\" \/>\r\n<meta property=\"og:site_name\" content=\"VCRO\" \/>\r\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/people\/\/100057388670681\/\" \/>\r\n<meta property=\"article:published_time\" content=\"2023-03-10T02:30:00+00:00\" \/>\r\n<meta property=\"article:modified_time\" content=\"2024-07-12T02:31:00+00:00\" \/>\r\n<meta property=\"og:image\" content=\"https:\/\/www.vcro.com.tw\/wp-content\/uploads\/2024\/07\/VCRO-logo-512-512-background-transparent.png\" \/>\r\n\t<meta property=\"og:image:width\" content=\"512\" \/>\r\n\t<meta property=\"og:image:height\" content=\"512\" \/>\r\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\r\n<meta name=\"author\" content=\"VCRO\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"VCRO\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1569#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1569\"},\"author\":{\"name\":\"VCRO\",\"@id\":\"https:\/\/www.vcro.com.tw\/#\/schema\/person\/2f08cc59b04b0a3bd4c58d32eb630c43\"},\"headline\":\"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial!\",\"datePublished\":\"2023-03-10T02:30:00+00:00\",\"dateModified\":\"2024-07-12T02:31:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1569\"},\"wordCount\":71,\"publisher\":{\"@id\":\"https:\/\/www.vcro.com.tw\/#organization\"},\"articleSection\":[\"VCRO express\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1569\",\"url\":\"https:\/\/www.vcro.com.tw\/?p=1569\",\"name\":\"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial! - VCRO\",\"isPartOf\":{\"@id\":\"https:\/\/www.vcro.com.tw\/#website\"},\"datePublished\":\"2023-03-10T02:30:00+00:00\",\"dateModified\":\"2024-07-12T02:31:00+00:00\",\"description\":\"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial! VCRO -\",\"breadcrumb\":{\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1569#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.vcro.com.tw\/?p=1569\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.vcro.com.tw\/?p=1569#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.vcro.com.tw\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.vcro.com.tw\/#website\",\"url\":\"https:\/\/www.vcro.com.tw\/\",\"name\":\"VCRO - Asia Pacific CRO Based in Taiwan\",\"description\":\"Virginia Contract Research Organization Co., Ltd.- Asia Pacific CRO Based in Taiwan\",\"publisher\":{\"@id\":\"https:\/\/www.vcro.com.tw\/#organization\"},\"alternateName\":\"VCRO\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.vcro.com.tw\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.vcro.com.tw\/#organization\",\"name\":\"Virginia Contract Research Organization Co., Ltd.\",\"alternateName\":\"VCRO\",\"url\":\"https:\/\/www.vcro.com.tw\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.vcro.com.tw\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/vcro.com.cn\/wp-content\/uploads\/2024\/07\/VCRO-logo-512-512-background-transparent.png\",\"contentUrl\":\"https:\/\/vcro.com.cn\/wp-content\/uploads\/2024\/07\/VCRO-logo-512-512-background-transparent.png\",\"width\":512,\"height\":512,\"caption\":\"Virginia Contract Research Organization Co., Ltd.\"},\"image\":{\"@id\":\"https:\/\/www.vcro.com.tw\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/people\/\/100057388670681\/\",\"https:\/\/line.me\/R\/ti\/p\/277jsobo\",\"http:\/\/weixin.qq.com\/r\/eRD64tPE0I6vrZeB90Vr\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.vcro.com.tw\/#\/schema\/person\/2f08cc59b04b0a3bd4c58d32eb630c43\",\"name\":\"VCRO\",\"sameAs\":[\"https:\/\/www.vcro.com.tw\"],\"url\":\"https:\/\/www.vcro.com.tw\/?author=1\"}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial! - VCRO","description":"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial! VCRO -","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.vcro.com.tw\/?p=1569","og_locale":"en_US","og_type":"article","og_title":"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial! - VCRO","og_description":"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial! VCRO -","og_url":"https:\/\/www.vcro.com.tw\/?p=1569","og_site_name":"VCRO","article_publisher":"https:\/\/www.facebook.com\/people\/\/100057388670681\/","article_published_time":"2023-03-10T02:30:00+00:00","article_modified_time":"2024-07-12T02:31:00+00:00","og_image":[{"width":512,"height":512,"url":"https:\/\/www.vcro.com.tw\/wp-content\/uploads\/2024\/07\/VCRO-logo-512-512-background-transparent.png","type":"image\/png"}],"author":"VCRO","twitter_card":"summary_large_image","twitter_misc":{"Written by":"VCRO"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.vcro.com.tw\/?p=1569#article","isPartOf":{"@id":"https:\/\/www.vcro.com.tw\/?p=1569"},"author":{"name":"VCRO","@id":"https:\/\/www.vcro.com.tw\/#\/schema\/person\/2f08cc59b04b0a3bd4c58d32eb630c43"},"headline":"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial!","datePublished":"2023-03-10T02:30:00+00:00","dateModified":"2024-07-12T02:31:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.vcro.com.tw\/?p=1569"},"wordCount":71,"publisher":{"@id":"https:\/\/www.vcro.com.tw\/#organization"},"articleSection":["VCRO express"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.vcro.com.tw\/?p=1569","url":"https:\/\/www.vcro.com.tw\/?p=1569","name":"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial! - VCRO","isPartOf":{"@id":"https:\/\/www.vcro.com.tw\/#website"},"datePublished":"2023-03-10T02:30:00+00:00","dateModified":"2024-07-12T02:31:00+00:00","description":"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial! VCRO -","breadcrumb":{"@id":"https:\/\/www.vcro.com.tw\/?p=1569#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.vcro.com.tw\/?p=1569"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.vcro.com.tw\/?p=1569#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.vcro.com.tw\/"},{"@type":"ListItem","position":2,"name":"Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial!"}]},{"@type":"WebSite","@id":"https:\/\/www.vcro.com.tw\/#website","url":"https:\/\/www.vcro.com.tw\/","name":"VCRO - Asia Pacific CRO Based in Taiwan","description":"Virginia Contract Research Organization Co., Ltd.- Asia Pacific CRO Based in Taiwan","publisher":{"@id":"https:\/\/www.vcro.com.tw\/#organization"},"alternateName":"VCRO","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.vcro.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.vcro.com.tw\/#organization","name":"Virginia Contract Research Organization Co., Ltd.","alternateName":"VCRO","url":"https:\/\/www.vcro.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.vcro.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/vcro.com.cn\/wp-content\/uploads\/2024\/07\/VCRO-logo-512-512-background-transparent.png","contentUrl":"https:\/\/vcro.com.cn\/wp-content\/uploads\/2024\/07\/VCRO-logo-512-512-background-transparent.png","width":512,"height":512,"caption":"Virginia Contract Research Organization Co., Ltd."},"image":{"@id":"https:\/\/www.vcro.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/people\/\/100057388670681\/","https:\/\/line.me\/R\/ti\/p\/277jsobo","http:\/\/weixin.qq.com\/r\/eRD64tPE0I6vrZeB90Vr"]},{"@type":"Person","@id":"https:\/\/www.vcro.com.tw\/#\/schema\/person\/2f08cc59b04b0a3bd4c58d32eb630c43","name":"VCRO","sameAs":["https:\/\/www.vcro.com.tw"],"url":"https:\/\/www.vcro.com.tw\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/1569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1569"}],"version-history":[{"count":1,"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/1569\/revisions"}],"predecessor-version":[{"id":1570,"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/1569\/revisions\/1570"}],"wp:attachment":[{"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vcro.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}